Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: the MARKED (Multi mARKer Emergency Dyspnea)-risk score.

[1]  P. Harst,et al.  The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.

[2]  I. Piña,et al.  Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study , 2012, Circulation. Heart failure.

[3]  I. Piña,et al.  Galectin-3 in Ambulatory Patients With Heart FailureClinical Perspective , 2012 .

[4]  J. Januzzi,et al.  Emerging biomarkers in heart failure. , 2012, Clinical chemistry.

[5]  M. Prins,et al.  Troponin T measurements by high-sensitivity vs conventional assays for risk stratification in acute dyspnea. , 2012, Clinical chemistry.

[6]  Alan S Maisel,et al.  Short-term mortality risk in emergency department acute heart failure. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[7]  S. Manzano-Fernández,et al.  Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.

[8]  J. Pérez-Calvo,et al.  Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. , 2011, European journal of internal medicine.

[9]  A. Khera,et al.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.

[10]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[11]  M. Picard,et al.  Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure , 2010, European journal of heart failure.

[12]  J. Aschoff,et al.  Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. , 2010, European heart journal.

[13]  Jinong Li,et al.  Analytical performance of 4 automated assays for measurement of cystatin C. , 2010, Clinical chemistry.

[14]  E. Adamopoulou,et al.  Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. , 2010, International journal of cardiology.

[15]  T. Mueller,et al.  Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. , 2010, Clinical biochemistry.

[16]  P. Ponikowski,et al.  Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[17]  A. Wu,et al.  Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. , 2010, Clinical biochemistry.

[18]  H. Hillege,et al.  Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study , 2010, Clinical Research in Cardiology.

[19]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[20]  K. Leunissen,et al.  Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  M. Pfeffer,et al.  A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.

[22]  S. Manzano-Fernández,et al.  Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. , 2009, The American journal of cardiology.

[23]  Yvonne Vergouwe,et al.  Prognosis and prognostic research: validating a prognostic model , 2009, BMJ : British Medical Journal.

[24]  F. Harrell,et al.  Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association , 2009, Circulation.

[25]  W. Wodzig,et al.  Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. , 2009, Clinical chemistry.

[26]  S. Réhman,et al.  Inflammatory markers, amino-terminal pro-brain natriuretic peptide, and mortality risk in dyspneic patients. , 2008, American journal of clinical pathology.

[27]  S. Réhman,et al.  Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[28]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[29]  M. Christ-Crain,et al.  Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. , 2008, Chest.

[30]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[31]  D. Lloyd‐Jones,et al.  A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme , 2007, Heart.

[32]  J. Cohn,et al.  Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.

[33]  John G F Cleland,et al.  Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. , 2007, American heart journal.

[34]  Claudio Passino,et al.  Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. , 2007, Clinical chemistry.

[35]  M. Nieminen,et al.  Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. , 2006, European heart journal.

[36]  P. Ellinor,et al.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. , 2006, Journal of the American College of Cardiology.

[37]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[38]  A. Levin,et al.  Prognostic Value of Troponin T and I Among Asymptomatic Patients With End-Stage Renal Disease: A Meta-Analysis , 2005, Circulation.

[39]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[40]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[41]  L. Fried,et al.  Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults , 2005, Annals of Internal Medicine.

[42]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.

[43]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. , 2004, Journal of the American Medical Association (JAMA).

[44]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .

[45]  W. Yin,et al.  Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. , 2004, American heart journal.

[46]  J. Cornuz,et al.  Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome , 2004, Thrombosis and Haemostasis.

[47]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[48]  A. Grubb.  Cystatin C-Properties and use as diagnostic marker , 2001, Advances in Clinical Chemistry.

[49]  E. Uhlmann,et al.  Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System, and correlation with creatinine. , 2001, Clinical Chemistry.

[50]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[51]  N Rifai,et al.  Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. , 2001, Clinical chemistry.

[52]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[53]  E W Steyerberg,et al.  Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. , 1999, Journal of clinical epidemiology.

[54]  E. Michelson,et al.  Evaluation of the patient with shortness of breath: an evidence based approach. , 1999, Emergency medicine clinics of North America.

[55]  A. Bühlmann.  [Pathophysiology of dyspnea]. , 1989, Schweizerische medizinische Wochenschrift.